CoChat

Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction

Open access
Golwala, Harsh B., Thadani, Udho, Liang, Li, Stavrakis, Stavros, Butler, Javed, Yancy, Clyde W., Bhatt, Deepak L., Hernandez, Adrian F., Fonarow, Gregg C. · 2013 · Journal of the American Heart Association
Cited by 41

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Hydralazine‐isosorbide dinitrate (H‐ ISDN ) therapy is recommended for A frican A merican patients with moderate to severe heart failure with reduced ejection fraction (<40%) ( HF r EF ), but use, temporal trends, and clinical characteristics associated with H‐ ISDN therapy in clinical practice are unknown. Methods and Results: An observational analysis of 54 622 patients admitted with HF r EF and discharged home from 207 hospitals participating in the Get With The Guidelines– H eart F ailure registry from April 2008 to March 2012 was conducted to assess prescription, trends, and predictors of use of H‐ ISDN among eligible patients. Among 11 185 A frican A merican patients eligible for H‐ ISDN therapy, only 2500 (22.4%) received H‐ ISDN therapy at discharge. In the overall eligible population, 5115 of 43 498 (12.6%) received H‐ ISDN at discharge. Treatment rates increased over the study period from 16% to 24% among A frican A mericans and from 10% to 13% among the entire HF r EF population. In a multivariable model, factors associated with H‐ ISDN use among the entire cohort included younger age; male sex; A frican A merican/Hispanic ethnicity; and history of diabetes, hypertension, anemia, renal insufficiency, higher systolic blood pressure, and lower heart rate. In A frican A merican patients, these factors were similar; in addition, being uninsured was associated with lower use. Conclusions: Overall, few potentially eligible patients with HF r EF are treated with H‐ ISDN , and among A frican‐ A mericans fewer than one‐fourth of eligible patients received guideline‐recommended H‐ ISDN therapy. Improved ways to facilitate use of H‐ ISDN therapy in A frican A merican patients with HF r EF are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.113.000214

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 41

Metadata

Authors
Golwala, H. B., Thadani, U., Liang, L., Stavrakis, S., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., & Fonarow, G. C.
Venue
Journal of the American Heart Association
Published
2013-08-22
Volume
2
Issue
4
Pages
e000214-e000214
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2121984641
Cited by
41
References
4
FWCI
2.75
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. https://app.cochat.ai/papers/10.1161/jaha.113.000214
The paper
Golwala, H. B., Thadani, U., Liang, L., Stavrakis, S., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., & Fonarow, G. C. (2013). Use of Hydralazine‐Isosorbide Dinitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.113.000214

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.